- Home
- HALO
as 05-30-2025 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $63.56 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.76 | EPS Growth: | 55.40 |
| 52 Week Low/High: | $42.01 - $70.50 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,084,306,000 | Revenue Growth: | 25.64% |
| Revenue Growth (this year): | 25.77% | Revenue Growth (next year): | 18.01% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | HALO | Director | Apr 28 '25 | Sell | $60.67 | 4,497 | $271,467.09 | 28,811 | |
| Henderson Jeffrey William | HALO | Director | Apr 1 '25 | Sell | $64.05 | 503 | $32,217.15 | 28,811 | |
| Henderson Jeffrey William | HALO | Director | Mar 3 '25 | Sell | $58.53 | 5,000 | $293,458.31 | 28,811 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Yahoo Finance
12 hours ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
12 hours ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
12 hours ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Reuters
12 hours ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
USA TODAY
12 hours ago
Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
Simply Wall St.
12 hours ago
Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
CBS News Videos
12 hours ago
Saturday Sessions: OK Go performs "Love"
Simply Wall St.
12 hours ago
We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.